INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $77,000 | -81.1% | 85,000 | -83.0% | 0.00% | – |
| Q1 2021 | $407,000 | +102.5% | 500,000 | +100.0% | 0.00% | – |
| Q3 2020 | $201,000 | -70.4% | 250,000 | -70.5% | 0.00% | -100.0% |
| Q1 2020 | $678,000 | +160.8% | 847,000 | +228.3% | 0.00% | – |
| Q4 2019 | $260,000 | -27.8% | 258,000 | -38.4% | 0.00% | – |
| Q3 2019 | $360,000 | +58.6% | 419,000 | +65.0% | 0.00% | – |
| Q2 2019 | $227,000 | -95.5% | 254,000 | -95.1% | 0.00% | -100.0% |
| Q1 2019 | $5,090,000 | +101.9% | 5,144,000 | +87.9% | 0.01% | +66.7% |
| Q4 2018 | $2,521,000 | -46.3% | 2,737,000 | -41.1% | 0.00% | -25.0% |
| Q3 2018 | $4,697,000 | -47.8% | 4,647,000 | -54.8% | 0.00% | -55.6% |
| Q2 2018 | $8,999,000 | +1.9% | 10,278,000 | -6.8% | 0.01% | +12.5% |
| Q1 2018 | $8,833,000 | +150.2% | 11,024,000 | +148.2% | 0.01% | +166.7% |
| Q4 2017 | $3,531,000 | +83.8% | 4,441,000 | +78.6% | 0.00% | +50.0% |
| Q3 2017 | $1,921,000 | -19.6% | 2,487,000 | +1.3% | 0.00% | 0.0% |
| Q2 2017 | $2,388,000 | +8.6% | 2,455,000 | +4.0% | 0.00% | 0.0% |
| Q1 2017 | $2,199,000 | +9.7% | 2,360,000 | +4.9% | 0.00% | 0.0% |
| Q4 2016 | $2,005,000 | -64.1% | 2,250,000 | -55.0% | 0.00% | -60.0% |
| Q3 2016 | $5,585,000 | – | 4,995,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|